DIABETIC NEUROPATHY MARKET ANALYSIS

Market News

Key Developments

1. Major players in the market are focused on various business strategies such collaboration and agreement, in order to gain the competitive edge in the market. For instance, in November 2018, NeuroMetrix, Inc., a health technology company, entered into a distribution agreement with Fukuda Denshi Co. Ltd. for DPNCheck. It is NeuroMetrix’s point-of-care test for diabetic peripheral neuropathy and the agreement will provide Fukuda exclusive distribution rights in Japan through March 2021.
2. Key players in the market are involved in various growth strategies such as gaining product approvals from regulatory authorities, in order to expand product portfolio and enhance the market presence. For instance, in October 2017, Pfizer, Inc. received the U.S. Food and Drugs Administration (FDA) approval for LYRICA CR extended release tables, which would be used once-a daily. These tablets are indicated for neuropathic pain related to diabetic peripheral neuropathy.
3. Key players in the market are involved in various growth strategies such as product launches, in order to expand product portfolio and gain competitive edge in the global market. For instance, in April 2019, Daiichi-Sankyo, Limited, a Japanese pharmaceutical company, launched ‘Tarlige’ tablets 2.5 mg, 5 mg, and 10 mg. These tables are indicated for patients with diabetic peripheral neuropathy.